[
  {
    "ts": null,
    "headline": "ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients",
    "summary": "AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator's choice (IC) chemot",
    "url": "https://finnhub.io/api/news?id=537c8f76fc8b4721330423f471d266a9f09b5446239c0dd4840620a900a41530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742040000,
      "headline": "ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients",
      "id": 133184479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator's choice (IC) chemot",
      "url": "https://finnhub.io/api/news?id=537c8f76fc8b4721330423f471d266a9f09b5446239c0dd4840620a900a41530"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?",
    "summary": "AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE®? in women with folate receptor alpha -positive platinum-resistant ovarian...",
    "url": "https://finnhub.io/api/news?id=c1bfdcdd96a3833b646fc59eac706c2d5ce4301fc0fcd43e46408f1a3ba9b0d2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742025600,
      "headline": "AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?",
      "id": 133178873,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE®? in women with folate receptor alpha -positive platinum-resistant ovarian...",
      "url": "https://finnhub.io/api/news?id=c1bfdcdd96a3833b646fc59eac706c2d5ce4301fc0fcd43e46408f1a3ba9b0d2"
    }
  }
]